Works Cited

1. Gervasini G, Benítez J, Carrillo J. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(8):755-774.

2. Wu AH. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. Arch Pathol Lab Med. 2013;137(9):1232-1236.

3. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. Last accessed April 23, 2021.

4. Kim S, Yun YM, Chae HJ, et al. Clinical pharmacogenetic testing and application: laboratory medicine clinical practice guidelines. Ann Lab Med. 2017;37(2):180-193.

5. Shah RR, Shah DR. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol. 2012;74(4):698-721.

6. Haga SB, Burke W, Ginsburg GS, Mills R, Agans R. Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012;82(4):388-394.

7. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326-331.

8. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 polymorphism and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.

9. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.

10. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7(8):1211-1221.

11. Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte: an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.

12. Pop TR, Chirită DN, Buzoianu AD. Pharmacogenetics of oral anticoagulant therapy. Hum Vet Med. 2013;5(1):9-13.

13. Flockhart DA, Skaar T, Berlin DS, Klein TE, Nguyen AT. Clinically available pharmacogenomics tests. Clin Pharmacol Ther. 2009;86(1):109-113.

14. Alonso SG, de la Torre Díez I, Zapiraín BG. Predictive, personalized, preventive and participatory (4P) medicine applied to telemedicine and eHealth in the literature. J Med Syst. 2019;43(5):140.

15. Cardon LR, Harris T. Precision medicine, genomics and drug discovery. Hum Mol Genet. 2016;25(R2):R166-R172.

16. Hood E. Pharmacogenetics: the promise of personalized medicine. Environ Health Perspect. 2003;111(11):A581-A589.

17. Haga SP, Burke W. Pharmacogenetic testing: not as simple as it seems. Genet Med. 2008;10(6):391-395.

18. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.

19. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12(13): 3908-3914.

20. Cavallari L, Shin J, Perera, MA. Role of pharmacogenetics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011;31(12):1192-1207.

21. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across three racial groups. Blood. 2010;115(18):3827-3834.

22. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13(12):3731-3737.

23. Cecchin E, Agostini M, Pucciarelli S, et al. Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. Pharmacogenomics J. 2011;11(3):214-226.

24. Dreussi E, Cecchin E, Polesel J, et al. Pharmacogenetics biomarkers and their specific role in neoadjuvant chemoradiotherapy treatments: an exploratory study on rectal cancer patients. Int J Mol Sci. 2016;17(9):1482.

25. Carrieri D, Bewshea C, Walker G, et al. Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting report. J Med Ethics. 2016;42(11):695-697.

26. Vogenberg FR, Barash CI, Pursel M. Personalized medicine, part 2: ethical, legal and regulatory issues. P T. 2010;35(11):624-626, 628-631, 642.

27. Hoop JG, Lapid MI, Paulson RM, Roberts LW. Clinical and ethical considerations in pharmacogenetic testing: views of physicians in three "early adopting" departments of psychiatry. J Clin Psychiatry. 2010;71(6):745-753.

28. Barash CI. Ethical Issues in Pharmacogenetics. Available at https://theatreofdebate.co.uk/wp-content/uploads/2020/12/Ethical-Issues-in-Pharmacogenetics-ActionBioscience.pdf. Last accessed April 23, 2021.

29. American Academy of Pediatrics. Ethical and policy in genetic testing and screening of children. Pediatrics. 2013;131(3):620-622.

30. Haga SB, Kantor A. Horizon scan of clinical laboratories offering pharmacogenetic testing. Health Aff (Millwood). 2018;37(5):717-723.

31. Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther. 2014;96(6):652-654.

32. Lazaridis KN. Improving therapeutic odyssey: preemptive pharmacogenomics utility in patient care. Clin Pharmacol Ther. 2017;101(1):39-41.

33. Bielinski SJ, Olson JE, Pathak J, et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin Proc. 2014;89(1):25-33.

34. Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89-106.

35. Feldman EA. The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med. 2012;27(6):743-746.

36. Caudle KE, Klein TE, Hoffman JM, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209-217.

37. Luzum JA, Pakyz RE, Elsey AR, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems. Clin Pharmacol Ther. 2017;102(3):502-510.

Evidence-Based Practice Recommendations Citations

1. Schaefer GB, Mendelsohn NJ, Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15(5):399-407. Available at https://www.acmg.net/PDFLibrary/Austism-Spectrum-Genetics-Evaluation.pdf. Last accessed April 28, 2021.


Copyright © 2021 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.